Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New Equine Virus test launched
NEV is often misdiagnosed or hidden by other diseases that cause similar symptoms.
Test to prevent misdiagnosis of often fatal disease

The first commercial diagnostic test for New Equine Virus (NEV) has been launched.

First discovered in 2013, NEV is often misdiagnosed or hidden by other diseases that cause similar symptoms, such as anaemia and neurological problems.

It is most often confused with the Swamp Fever virus (EIAV) and Equine Herpesvirus (EHV).

Now, thanks to research by equine biotech firm Equigerminal, vets, laboratories and horse owners will be able to identify this often fatal disease and administer the appropriate treatment.

The test requires a vet to take a blood sample from the horse and send it to the Equigerminal lab. The blood is then analysed and the results are returned to the owner or vet.

When the results are returned, the horse can be given treatment and the spread of the disease can be prevented. Currently, treatment is aimed towards improving the general wellbeing of the horse, monitoring its health and boosting the immune system.

NEV was discovered by Portuguese scientist and veterinary surgeon Isabel Fidalgo Carvalho while completing her PhD in Equine Sciences at the Universities of Oporto and Pittsburgh.

“During my time at University and at Equigerminal, I noticed unusual anaemia and severe neurological signs in horses, which in my PhD I wrongly hypothesized to be attributed to Swamp Fever,” she said. “I then realised, through the samples, that this virus was actually closer to equine HIV – New Equine Virus, or NEV”.

After her discovery, Carvalho launched Equigerminal with fellow scientist Alexandre Vieira Pires.

“We have spent the last five years developing a diagnostic test and a potential cure for NEV.” explains Pires.“We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

Become a member or log in to add this story to your CPD history

VMD responds to Solensia injection concerns

News Story 1
 The VMD has added anaphylaxis to the SPC of Solensia 7 mg/ml Solution for Injection for Cats.

It says that this is a rare side effect, with such adverse events affecting fewer than three animals for every 1000 doses of Solensia sold.

Solensia is used to alleviate osteoarthritis pain in cats. It contains the active ingredient frunevetmab.

Anaphylaxis joins effects such as alopecia, dermatitis, pruritus on the list of adverse effects.

The VMD says that is constantly reviewing adverse event data for all medicines. 

Click here for more...
News Shorts
Applications open for RCVS Fellowship

The Royal College of Veterinary Surgeons (RCVS) has opened applications for veterinary surgeons to join the RCVS Fellowship.

The RCVS Fellowship is a learned society which works to advance veterinary standards and promote scientific excellence.

Veterinary surgeons can enter the RCVS Fellowship through three routes, each with different criteria. This enables people with a range of expertise and experience to join the society.

The routes are: Meritorious Contributions to Clinical Practice, Meritorious Contributions to Knowledge and Meritorious Contributions to the Profession.

Applicants must share a summary of their contributions to the profession, including examples of significant works produced throughout their career. The application will then be assessed by a panel of judges against a set of criteria.

Veterinary surgeons have until 4pm on Friday, 14 March to submit applications. More information, including requirements and guidance can be found here.